Human Lymphokine-Activated Killer Cells and Their Potential for Cancer Therapy
Data from numerous animal tumor models have led to the consensus that the cellular immune system contains the capacity to regulate autologous tumor growth. Differences exist with respect to the observed effector system(s) responsible for tumor regression: monocytes, helper T cells, killer T cells of varying and distinct phenotypes, cell populations expressing natural killer (NK) activity, and lymphokine-activated killer (LAK) cells each have been reported to be operative in the regulation of cancer. The recent development of DNA-produced immunological “hormones,” often called “cytokines,” has provided an unequaled opportunity to study basic aspects of immune regulation. In the USA, as well as in several other countries, the public has become increasingly aware of and interested in the potential therapeutic application of these cytokines, and hence they are already in the initial stages of testing for their value in cancer therapy.
KeywordsAdoptive Therapy Autologous Lymphocyte Peripheral Blood Lympho Autochthonous Tumor Stromal Cell Sarcoma
Unable to display preview. Download preview PDF.
- 1.Grimm EA, Mazumder A, Rosenberg SA (1982) In vitro growth of cytotoxic human lymphocytes. V. Generation of allospeciflc cytotoxic lymphocytes to nonimmunogenie antigen by supplementation of in vitro sensitization with partially purified T cell growth factor ( PP-TCGF ). Cell Immunol 70: 248–259Google Scholar
- 3.Grimm EA, Rosenberg SA (1984) The human lymphokine-activated killer cell phenomenon. In: Pick E (ed) The lymphokines. Academic, New York, pp 279–311Google Scholar
- 4.Grimm EA (1986) Lymphokine activated killing. BBA Rev Cancer 865 (3): 267–279Google Scholar
- 6.Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer MC, Rosenberg SA (1985) In vivo administration of purified human interleukin–2. II. Half-life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL–2. J Immunol 135: 2865–2875PubMedGoogle Scholar
- 7.Bradley EC, Doyle M, deGroat S, Damle NK, Doyle LV, Rudolph AR, Issell BF (1987) LAK induction in vivo in patients treated with interleukin–2 may be necessary for tumor regression. Proc Am Assoc Cancer Res 28: 407Google Scholar
- 8.Phillips JH, Gemlo BT, Myers WW, Rayner AA, Lanier LL (1987) In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin–2 and LAK cell therapy. J Clin Oncol 5:1933–1941 Rosenberg SA, Lotze MT, Muul LM(1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin–2 to patients with metastatic cancer. New Engl J Med 313: 1485–1492Google Scholar
- 14.Pizza G, Severini G, Menniti D, De Vinci C, Corrado F (1984) Tumor regression after intralesional injection of interleukin–2 (IL–2) in bladder cancer. Preliminary report. Int J Cancer 34: 359–369Google Scholar